Project Grant R01NS138515
Award Date 8/4/25
Completion Date 7/31/30
Dollars Obligated $339K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
- This Project Grant award of $687,279 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to uncover the effects of standard-of-care therapy on immune and neoplastic cell population dynamics in pre-clinical mouse models of glioblastoma (GBM) and analysis of human GBM samples. The goal is to identify tumor microenvironment areas of therapeutic...
- This Project Grant award of $652,751 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to engineer antibody drug conjugates (ADCs) designed to enhance the therapeutic window for treating glioblastoma (GBM) and other central nervous system cancers. The research, conducted by the Mayo Clinic, aims to leverage key findings from prior preclinical studies...
- This $138,189 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop a glioblastoma stem cell (GSC) vaccine for the prevention and control of the aggressive and incurable brain cancer glioblastoma (GBM). The research, conducted by North Carolina Agricultural and Technical State University, aims to assess the vaccine's...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $229,078 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of North Carolina at Chapel Hill to investigate "Ferroptosis Sensitization in Glioblastoma". The project aims to leverage positron emission tomography (PET) imaging with the FSPG tracer to study the effects of dietary cysteine/methionine deprivation and radiation...
- This $638,697 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) to investigate the role of the SMARCA5 protein in the development and progression of glioblastoma, an aggressive type of brain cancer. The goal of the research is...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, will fund research to target cell-scaffolding proteins that contribute to radioresistance in glioblastoma, an aggressive brain cancer. The $448,250 award to The Research Foundation For The State University Of New York, operating as Upstate Medical Center, will support a 2-year...
- This federal Project Grant award for $659,325.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to understand the role of mutant IDH1 in glioma pathophysiology and immune response mechanisms. The research will use a novel murine glioma model developed by incorporating genetic lesions into neural progenitor cells using the...
- This federal Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to explore the mechanism of Notch inhibition resistance in glioblastoma (GBM) cancer stem-like cells. The goal is to develop novel therapies for this deadly brain cancer. The research project, led by the Regents of the University of Michigan, will identify GBM...
- This federal Project Grant award of $131,360 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding research at the University of New Haven to characterize the long non-coding RNA GIHCG and assess its potential as a therapeutic target for glioblastoma, the most aggressive form of brain cancer. The 4-year project aims to use CRISPR/Cas9 gene editing to...
- The National Institute of Neurological Disorders and Stroke (NINDS), through its Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $420,251 Project Grant to Brigham & Women's Hospital Inc. on May 6, 2025. The grant supports the development of an encapsulated cell-based oncolytic virus therapy for the treatment of glioblastoma (GBM), the most lethal primary brain tumor. The research aims to enhance the therapeutic efficacy of engineered...